Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MATULANE vs AURLUMYN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Matulane (procarbazine) is a prodrug that undergoes metabolic activation to generate cytotoxic alkylating metabolites. It inhibits DNA, RNA, and protein synthesis through methylation of nucleic acids and proteins, and may also inhibit monoamine oxidase.
Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.
Treatment of advanced Hodgkin lymphoma (in combination with other drugs),Treatment of non-Hodgkin lymphoma (off-label),Treatment of brain tumors (off-label)
Treatment of relapsed or refractory multiple myeloma,Treatment of relapsed or refractory mantle cell lymphoma
200-300 mg orally once daily for 10-14 days as part of MOPP regimen; maintenance dose: 50-100 mg orally once daily after hematologic recovery.
Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.
Terminal elimination half-life is approximately 7-10 hours (range 5-15 hours) in adults; context: prolonged in hepatic or renal impairment.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Procarbazine is metabolized primarily by the liver via oxidation by CYP450 enzymes and other oxidases to active metabolites. It also undergoes some metabolism by monoamine oxidase (MAO) in the liver and other tissues.
Primarily metabolized by CYP3A4 and to a lesser extent by CYP1A2 and CYP2C8.
Primarily renal (approximately 50-60% as unchanged drug and metabolites) and fecal (approximately 10-20%); minor biliary excretion.
Primarily renal excretion of unchanged drug (60-70%) with biliary/fecal elimination accounting for 20-30%.
Approximately 10-20% bound to plasma proteins (mainly albumin); minimal binding.
Approximately 85-90% bound to serum albumin.
Approximately 3-4 L/kg; indicates extensive tissue distribution including brain (penetrates CNS).
0.5 L/kg, indicating distribution primarily into extracellular fluid with limited tissue penetration.
Oral bioavailability is nearly complete (close to 100%) after oral administration.
Oral bioavailability is 50-60% due to first-pass metabolism and incomplete absorption.
GFR ≥50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose to 50-75%; GFR <10 m L/min: avoid use or reduce to 50% and monitor.
GFR ≥30 m L/min: no adjustment. GFR <30 m L/min: not recommended (no data).
Child-Pugh A: 100% of dose; Child-Pugh B: reduce by 50%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended (no data).
Based on BSA: 100 mg/m2 orally once daily for 14 days as part of MOPP; or 50 mg/m2 orally on days 1-14.
Not established; safety and efficacy not determined in pediatric patients.
Start at lower end of dosing range (e.g., 200 mg daily) due to increased risk of myelosuppression and renal/hepatic impairment; monitor CBCs closely.
No specific dose adjustment; monitor renal function and hematologic toxicity more frequently.
Procarbazine is carcinogenic, mutagenic, and teratogenic. It should be used only by physicians experienced in cancer chemotherapy. Patients receiving procarbazine should be carefully monitored for hematologic toxicity.
None.
Bone marrow suppression (leukopenia, thrombocytopenia, anemia) requires dose adjustment; discontinue if toxicity is severe. CNS effects (drowsiness, depression, confusion) may occur. Disulfiram-like reaction with alcohol. Hypertensive crisis can occur with tyramine-rich foods or sympathomimetics due to MAO inhibition. Monitor for secondary malignancies. Fetal harm can occur; avoid pregnancy.
Hematologic toxicity (neutropenia, thrombocytopenia, anemia), infection risk, peripheral neuropathy, cardiotoxicity (heart failure), embryo-fetal toxicity.
Hypersensitivity to procarbazine; concomitant use with MAO inhibitors, tricyclic antidepressants, or other drugs with MAO-inhibiting activity; severe bone marrow depression; pregnancy.
Hypersensitivity to AURLUMYN or any of its components.
Avoid tyramine-rich foods: aged cheeses (cheddar, Swiss), cured meats (salami, pepperoni), fermented soy products (tofu, miso), sauerkraut, pickled herring, broad bean pods, yeast extracts, red wine, beer, and draft beers. Also avoid alcohol completely due to additive CNS depression.
Avoid alcohol. No specific food interactions, but maintain a balanced diet. Take with food or milk if gastrointestinal upset occurs.
Matulane (procarbazine) is a known teratogen. First trimester exposure is associated with major congenital malformations. Second and third trimester exposure carries risk of intrauterine growth restriction, fetal bone marrow suppression, and potential carcinogenesis. Use contraindicated in pregnancy.
First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and preterm birth. Avoid in pregnancy unless benefit outweighs risk.
Procarbazine is excreted into breast milk. M/P ratio not reported. Due to potential for carcinogenicity and adverse effects in the nursing infant, breastfeeding is contraindicated during matulane therapy and for at least 2 weeks after last dose.
No data on excretion in human milk; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose.
No well-established safe dose in pregnancy. If therapy is deemed essential despite risks, significant dose reduction and increased monitoring advised. Pharmacokinetic changes in pregnancy may alter procarbazine metabolism, but specific dose adjustments are not defined. Use only in life-threatening conditions with expert consultation.
No specific dosing adjustments established for pregnancy. Pregnancy-induced pharmacokinetic changes (increased volume of distribution, enhanced renal clearance) may reduce drug exposure; consider therapeutic drug monitoring if available.
Matulane (procarbazine) is a monoamine oxidase inhibitor (MAOI); concurrent use with sympathomimetics, tyramine-rich foods, or tricyclic antidepressants can precipitate hypertensive crisis. It is also a potent CNS depressant; avoid alcohol. Monitor for leukopenia and thrombocytopenia; nadir typically occurs 2-4 weeks after therapy. Discontinue if hypersensitivity pneumonitis occurs.
AURLUMYN is a proprietary name for auranofin, an oral gold compound used for rheumatoid arthritis. Monitor for oral ulcerations, dermatitis, and proteinuria. Renal function and CBC should be checked monthly. Avoid concurrent use with penicillamine, antimalarials, immunosuppressants, or cytotoxic drugs. Onset of action may be delayed 3-6 months.
Avoid foods high in tyramine such as aged cheeses, cured meats, fermented foods, and alcoholic beverages (especially beer and red wine) to prevent severe high blood pressure.,Do not take any over-the-counter medications, especially cold, sinus, or allergy medications, without consulting your doctor due to risk of drug interactions.,This drug may cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Report any signs of infection (fever, sore throat), unusual bleeding/bruising, or shortness of breath immediately.,Use effective contraception during treatment and for at least 1 month after stopping, as this drug can harm an unborn baby.
Take exactly as prescribed; do not adjust dose without consulting your doctor.,Report any mouth sores, skin rash, unexplained bruising, or change in urine color immediately.,Regular blood and urine tests are required to monitor for side effects.,May take 3-6 months to feel full benefit; do not stop suddenly.,Avoid alcohol as it may increase risk of liver toxicity.,Use effective contraception during treatment and for 6 months after stopping.,Do not take any other medications (including OTC) without approval from your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MATULANE vs AURLUMYN, answered by our medical review team.
MATULANE is a Antineoplastic Agent that works by Matulane (procarbazine) is a prodrug that undergoes metabolic activation to generate cytotoxic alkylating metabolites. It inhibits DNA, RNA, and protein synthesis through methylation of nucleic acids and proteins, and may also inhibit monoamine oxidase.. AURLUMYN is a Antineoplastic Agent that works by Microtubule inhibitor that binds to tubulin and disrupts microtubule dynamics, leading to mitotic arrest and apoptosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MATULANE and AURLUMYN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MATULANE is: 200-300 mg orally once daily for 10-14 days as part of MOPP regimen; maintenance dose: 50-100 mg orally once daily after hematologic recovery.. The standard adult dose of AURLUMYN is: Intravenous, 6 mg/kg every 4 weeks for 6 cycles; each cycle: Days 1 and 15 of a 28-day cycle.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MATULANE and AURLUMYN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MATULANE is classified as Category C. Matulane (procarbazine) is a known teratogen. First trimester exposure is associated with major congenital malformations. Second and third trimester exposure carries risk of intrau. AURLUMYN is classified as Category C. First trimester: Increased risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and limited human data. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.